LONDON, June 13, 2013 /PRNewswire/ —

Magicool Plus range of OTC topical, Class IIa sprays were recently listed in the NHS Drug Tariff part IX, under a specially created category and is available on prescription and OTC. The range comprises Magicool Plus Prickly Heat, Magicool Plus Itchy Skin due to Summer Ailments and Magicool Plus Sunburn, for treating mild to severe forms of the respective conditions.

Magicool Plus range of pioneering medical sprays, are free from steroids and anti-histamines and are the very first and only sprays to be listed in the NHS for the instant treatment of Prickly Heat, Itchy Skin due to Summer Ailments and Sunburn, in adults, children, infants from birth, pregnant women and those intolerant to the side effects of traditional treatment.

The above next-generation, patented sprays are clinically proven to work instantly and to achieve long lasting effect. Its unique “Instant T-CNS Signalling System”™ delivery technology allows a number of stimuli e.g. chemical, thermal and mechanical to be applied topically and simultaneously on the affected areas achieving greater efficacy than when applying each stimulus in turn. Such stimuli acting collectively are a powerful therapeutic tool, as millions of signals are communicated to the CNS via neurotransmitters which instantly trigger the effective treatment of the condition.

This proprietary “Instant T-CNS Signalling System”™ delivery technology, protected by 26 granted patents worldwide, comprises an advanced transcutaneous to CNS instant signalling system, functioning across the nano/microparticle spectrum. The optimum therapeutic particle size (mechanical energy), formulation (chemical energy) and measured cooling (thermal energy) are engineered to achieve maximum therapeutic efficacy for various indications, creating a family of sprays for a number of medical conditions e.g. in Dermatology, Paediatrics, Emergency Medicine, Gynaecology and Ophthalmology.

The NHS listing process entailed thorough evaluation by the NHS Prescription Services of the efficacy, safety and cost effectiveness of the Magicool Plus range when compared with traditional treatment in clinical trial studies.

FranceMed Pharma is a privately owned British company, established since 1981 and active in OTC Research, Development, Manufacturing and Global Marketing. Its OTC product range is available mainly in UK supermarkets and chemists. This range is being enriched by a significant portfolio of pioneering, clinically proven OTC products due to leave the pipeline shortly.

http://www.francemedpharma.com

SOURCE FranceMed Pharma